Pharminent

Happy Health’s cuffless blood pressure ring wins FDA clearance

Happy Health received FDA clearance for a wearable ring that continuously measures blood pressure without a cuff or external calibration.

Analysis finds pharma-funded group ties among FDA panel patient representatives

An analysis found that nearly 40 percent of FDA advisory committee meetings over a 20-year period included a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies.

BioNTech’s mRNA immunotherapy misses first objective in head and neck cancer

An early data check showed BioNTech’s mRNA cancer immunotherapy did not delay tumor progression in HPV16-positive head and neck cancer. The company said it will wait for further data, including on survival, before deciding the program’s fate.

Roche licenses Rona’s ALK7-targeting RNAi obesity drug in $1B pact

Roche and Rona Therapeutics entered a global license agreement worth about $1 billion for an ALK7-targeting RNAi therapy aimed at lowering visceral fat.

Pfizer and Enodia sign $500M Sec61 inhibitor research deal

Pfizer and Enodia Therapeutics announced a research collaboration and licensing agreement potentially worth more than $500 million to discover and develop Sec61 inhibitors.

Charles River partners with Magellan Stem Cells on Zelestrocel

Charles River Laboratories has entered a collaboration with Australian biotechnology firm Magellan Stem Cells to advance development and clinical progress of Magellan’s regenerative medicine candidate Zelestrocel.

Ofichem agrees to acquire US drug substance CDMO Kinentia

Dutch company Ofichem has agreed to acquire Kinentia Biosciences, a drug substance CDMO based in Rensselaer, New York, that supports early-stage development, preclinical programs and clinical development. The transaction has not yet closed.

BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8B

BlackRock is acquiring a majority stake in Humana’s CenterWell Senior Primary Care clinics for $2.8 billion, replacing Welsh, Carson, Anderson & Stowe as the private equity sponsor.

J&J raises 2026 guidance as Tremfya drives third-quarter immunology sales

Johnson & Johnson reported strong third-quarter results led by Tremfya’s immunology sales and raised its 2026 guidance, despite several products facing generic and biosimilar competition.

Velaris to go public through reverse merger with Alaunos

Paragon spinout Velaris is going public through a reverse merger with Alaunos, a deal backed by key investor Fairmount.

Cori Clinical raises $4M seed round for trial design AI platform

Cori Clinical raised $4 million in a seed round led by Breega, with participation from Enzo, Heartfelt, Together Ventures and Bynd, to expand its AI platform for clinical trial design and grow its team.

Arletta Pharma Solutions appoints Jeannette Jager-van Dijk as CEO

Netherlands-based clinical-stage biopharmaceutical company Arletta Pharma Solutions, which develops therapies for female sexual disorders, has appointed Jeannette Jager-van Dijk as chief executive officer. She has more than three decades of leadership experience in women’s health, vaccines and specialty pharmaceuticals.